8RQO | pdb_00008rqo

Human thyroid hormone receptor alpha ligand binding domain in complex with beta-selective agonist ALG-055009


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.74 Å
  • R-Value Free: 
    0.228 (Depositor), 0.232 (DCC) 
  • R-Value Work: 
    0.193 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 
    0.195 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 8RQO

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-beta ) Agonist for the Treatment of MASH.

Vandyck, K.McGowan, D.C.Luong, X.G.Stevens, S.K.Jekle, A.Gupta, K.Misner, D.L.Chanda, S.Serebryany, V.Welch, M.Hu, H.Lv, Z.Williams, C.Maskos, K.Lammens, A.Stoycheva, A.D.Lin, T.I.Blatt, L.M.Beigelman, L.N.Symons, J.A.Raboisson, P.Deval, J.

(2024) J Med Chem 67: 14840-14851

  • DOI: https://doi.org/10.1021/acs.jmedchem.4c01029
  • Primary Citation Related Structures: 
    8RQN, 8RQO

  • PubMed Abstract: 

    Agonists of thyroid hormone receptor β (THR-β) decreased LDL cholesterol (LDL-C) and triglyceride (TG) levels in human clinical trials for patients with dyslipidemia. The authors present the highly potent and selective compound ALG-055009 ( 14 ) as a potential best in class THR-β agonist. The high metabolic stability and good permeability translated well in vivo to afford a long in vivo half-life pharmacokinetic profile with limited liability for DDI, and it overcomes certain drawbacks seen in recent clinical candidates.


  • Organizational Affiliation
    • Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.

Macromolecule Content 

  • Total Structure Weight: 32.77 kDa 
  • Atom Count: 2,099 
  • Modeled Residue Count: 257 
  • Deposited Residue Count: 284 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Isoform Alpha-1 of Thyroid hormone receptor alpha284Homo sapiensMutation(s): 0 
Gene Names: THRAEAR7ERBA1NR1A1THRA1THRA2
UniProt & NIH Common Fund Data Resources
Find proteins for P10827 (Homo sapiens)
Explore P10827 
Go to UniProtKB:  P10827
PHAROS:  P10827
GTEx:  ENSG00000126351 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP10827
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1H2J
(Subject of Investigation/LOI)

Query on A1H2J



Download:Ideal Coordinates CCD File
B [auth A]6-azanyl-2-[3,5-bis(chloranyl)-4-[(6-oxidanylidene-5-propan-2-yl-1~{H}-pyridazin-3-yl)oxy]phenyl]-1,2,4-triazine-3,5-dione
C16 H14 Cl2 N6 O4
YZZBNKVFMULQCU-UHFFFAOYSA-N
SO4

Query on SO4



Download:Ideal Coordinates CCD File
C [auth A]SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.74 Å
  • R-Value Free:  0.228 (Depositor), 0.232 (DCC) 
  • R-Value Work:  0.193 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 0.195 (Depositor) 
Space Group: P 65 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 110.199α = 90
b = 110.199β = 90
c = 134.579γ = 120
Software Package:
Software NamePurpose
XDSdata reduction
XSCALEdata scaling
REFMACrefinement
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-09-11
    Type: Initial release
  • Version 1.1: 2024-09-25
    Changes: Database references